Leerink Partnrs Has Pessimistic View of CRBU FY2029 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at Leerink Partnrs dropped their FY2029 earnings estimates for shares of Caribou Biosciences in a note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of $0.26 for the year, down from their previous forecast of $0.28. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. The company had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

CRBU has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a report on Wednesday, March 19th. Bank of America decreased their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Stock Performance

Shares of CRBU opened at $0.74 on Thursday. Caribou Biosciences has a fifty-two week low of $0.66 and a fifty-two week high of $4.21. The firm has a 50-day simple moving average of $1.03 and a 200-day simple moving average of $1.57. The company has a market capitalization of $68.36 million, a price-to-earnings ratio of -0.45 and a beta of 2.36.

Institutional Trading of Caribou Biosciences

Large investors have recently made changes to their positions in the stock. Ancora Advisors LLC grew its position in shares of Caribou Biosciences by 16.0% in the fourth quarter. Ancora Advisors LLC now owns 58,000 shares of the company’s stock valued at $92,000 after purchasing an additional 8,000 shares during the period. Price T Rowe Associates Inc. MD grew its position in Caribou Biosciences by 28.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 35,848 shares of the company’s stock valued at $57,000 after acquiring an additional 8,008 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Caribou Biosciences by 4.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 176,654 shares of the company’s stock worth $281,000 after buying an additional 8,199 shares during the period. Milestone Asset Management LLC increased its position in shares of Caribou Biosciences by 5.6% during the fourth quarter. Milestone Asset Management LLC now owns 163,789 shares of the company’s stock worth $260,000 after acquiring an additional 8,662 shares during the last quarter. Finally, MetLife Investment Management LLC increased its holdings in Caribou Biosciences by 60.0% during the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock worth $39,000 after purchasing an additional 9,148 shares during the last quarter. Institutional investors and hedge funds own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.